Overactive Bladder
Conditions
Brief summary
To evaluate the safety and feasibility of non-invasive magnetic stimulation of the posterior tibial nerve using the EMKinetics LoFIT Pulse System for treating patients with documented overactive bladder.
Interventions
DEVICEEMKinetics non-invasive Magnetic neurostimulator
Patients will be treated with 12 weekly sessions of magnetic stimulation of the posterior tibial nerve at 20 hz using the EMKinetics non-invasive Magnetic neurostimulator.
Sponsors
EMKinetics, Inc
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Women \>18 years of age * A score of \> 4 on the OAB-q short form for urgency (question 1) * Average urinary frequency \> 10 times in one 24 hour day based on a 3-day voiding diary * Self-reported bladder symptoms present \> 3 months * Self-reported failed conservative care (e.g., dietary restriction, fluid restriction, bladder training, behavioral modification, pelvic muscle training, biofeedback, etc.) or use of antimuscarinics. * Off all anti-muscarinics for at least 2 weeks prior to enrollment * Capable of giving informed consent * Ambulatory and able to use a toilet independently, without difficulty * Capable and willing to follow all study-related procedures
Exclusion criteria
* The patient is pregnant or intends to become pregnant during the course of the study. (Patients becoming pregnant during the course of the study will immediately be terminated from the study.) * The patient has an active urinary tract infection. * Neurogenic bladder * Botox use in bladder or pelvic floor muscles in the past year * Pacemakers or implantable defibrillators * Primary complaint of stress urinary incontinence * Current vaginal infection * Current use of InterStim * Current use of Bion * Current use of TENS in the pelvic region, back or leg * Previously been treated with PTNS * Use of investigational drug/device therapy within the past 4 weeks * Participating or have participated within the past 4 weeks in any clinical investigation involving or impacting gynecologic, urinary or renal function * Deemed unsuitable for enrollment in study by the investigators based on subjects' history or physical examination * The patient has metal implant from surgery or a metallic foreign body in either leg below (distal to) the knee (or permanent metallic tattoo \<30cm from left ankle). * The patient has chronic constipation (less than two (2) bowel movements per week) * The patient has history of gastric or urinary retention * The patient has uncontrolled diabetes * Subjects with nerve damage, injury or surgery that would impact either tibial nerve or pelvic floor function * The patient is unable or unwilling to sign informed consent * The patient is currently on pharmacologic treatment that could affect bladder function * Known Cystocele \>/= to Grade 3 that has not been reduced by treatment (surgery or pessary)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Global Response Assessment | After 12 weeks of therapy | Improved score on the Global Response Assessment (GRA) scale after 12 weeks of therapy. A score of 2 (moderately improved) or 3 (markedly improved) constitutes a responder on the 7 point scale |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Urinary Frequency | After 12 weeks of therapy | Change in Urinary Frequency (Voiding Diary) from Baseline to 12 weeks |
| Urinary Incontinence | After 12 weeks of therapy | Change in Urinary Incontinence (Voiding Diary) from Baseline to 12 weeks |
| Overactive Bladder Symptoms (OAB-q SF) | After 12 weeks of therapy | Change in Overactive Bladder Symptoms (OAB-q SF) from Baseline to 12 weeks |
Countries
United States
Outcome results
None listed